A company focused on oncology and international leadership in healthcare.

Boston Oncology

Bold and nimble, Boston Oncology is an innovative biogenerics company redefining excellence in the licensing and local development, manufacturing and distribution of US- quality medicines – across therapeutic areas.

From our nerve center in Riyadh, we leverage the expertise, daring creativity, and unwavering determination of our international leadership team to provide customers with end-to-end, efficient, single-point-of-contact access to our diverse portfolio of world-class biogenerics.

We do this because lives depend on it.

CEO, Abdullah Baaj, MD, PharmD addressing the 2023 US Pharma Partnering Summit assembly hall—presenting the achievements and value of our innovative localization model for ROW markets. Thank you to the organizers for including Boston Oncology in this impactful event!

#PharmaPartnering #Lifescience #BostonOncology #BostonOncologyArabia #Pharmaceutical #ROWmarkets #HealthEquity #Licensing #Localization #Generics #GenericDrugs #Biosimilars #B2Bpartnering

We are excited to join forces with TVM Capital Healthcare in our mission to serve 1 billion people by 2030. This $35 million investment will expand the localization of our manufacturing, significantly enhancing the accessibility and quality of healthcare in the region. Looking forward to the journey ahead!

World Kidney Cancer Day

This year’s theme, “Listening,” serves as a two-fold reminder of the importance of paying attention to our own bodies and the power of listening carefully to patients’ experiences, needs and concerns.

Kidney cancer often has no symptoms in its early stages. Regular screenings, especially for those with risk factors such as smoking, obesity or family history, are essential.

By spreading awareness and encouraging proactive healthcare, we support informed and empowered patients—improving survival rates and quality of life for those affected by kidney cancer.

#WorldKidneyCancerDay #Listening #PatientEmpowerment #KidneyCancerAwareness #HumanizingHealthcare #BostonOncology #BostonOncologyArabia

World Ovarian Cancer Day

Often called the "silent killer," ovarian cancer is typically diagnosed in later stages. Symptoms are frequently dismissed as common digestive or menstrual issues--bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary urgency or frequency. 

Understanding the symptoms, regular medical check-ups, and access to treatment can lead to earlier diagnosis and better outcomes.

Boston Oncology is commitment to advocating for women's health and enhancing health equity by bringing affordable best-in-class oncology products to patients around the world.

#WorldOvarianCancerDay #OvarianCancerAwareness #OvarianCancer #KnowTheSigns #BostonOncology #BostonOncologyArabia

Innovating to Improve Access

The Boston Oncology team are thrilled to see our friends at Immuneel Therapeutics Pvt. Ltd. recognized among the 2023 Endpoints 11—celebrating the boldest startups with the most promising science.  

Richly deserved and arguably overdue, the accolade is especially meaningful bestowed upon a company leveraging truly disruptive #innovation to bring life-saving therapeutics to the developing world—at a small fraction of the accepted cost.

Making CAR-T accessible in India, and ultimately far beyond, is another brilliant example of the unwavering commitment of Co-Founder Kiran Mazumdar Shaw to providing affordable access to cutting-edge therapies around the globe.

Innovation is at the core the Immuneel model—from their efficient operations to their embedded facilities. Co-Founder Dr. Siddhartha Mukherjee said it best:  

“Access and innovation are inextricably linked. They are not opposed to one another. Innovation doesn’t necessarily mean making a new biological reagent. It might mean solving an engineering problem. It might mean running a new kind of trial. It might mean solving supply-chain issues.”

Wonderful recognition for an extraordinary team! And, they are just getting started. 

#Immuneel #Endpoints #EndpointsNews #Endpoints11 #SiddharthaMukherjee #DrSiddharthaMukherjee #KiranMazumdarShaw #BostonOncology #PatientCare #MedicalAccess #CellAndGeneTherapy #India #CartCellTherapy #CancerResearch

Metric
Company Name	Boston Oncology
Symbol
MSH ID	COM:BOSTONONCOLOGY
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Oncology
Country	US
Stage
Employee Count	45
Website	bostononcology.com
LinkedIn	boston-oncology-llc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:BOSTONONCOLOGY

Boston Oncology

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue